Clinical Trials

The clinical activities of ADARC are now part of the CUIMC Department of Infectious Diseases.

We are now conducting a clinical trial of a unique monoclonal antibody that has one arm that attaches to cells that have the receptor required for HIV to enter the cell, the CD4 receptor, and has another arm that attaches to a very well conserved portion of the HIV envelope. This is called a bispecific antibody because it binds to two regions. It is very potent and active against a broad range of HIV virus variants because it is designed to put the antibody at the precise location where it is needed.

The clinical trial is a Phase 1 study led by Dr. David Ho, the study Principal Investigator, and Dr. Magda Sobieczcyk, the CUIMC clinical trial Principal Investigator. The bispecific antibody is given as a single infusion and is recruiting HIV infected and uninfected individuals. To date a total of 42 subjects of a total of 57 have been given the monoclonal antibody infusion in increasing doses safely. Eligible participants are expected to complete 11 visits over 168 days of participation.

  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    Almost 40,000 people get HIV in the U.S. each year and almost all occur via sexual contact, especially male-to-male contact. The number of new infections has decreased slightly each year, however, we need other HIV prevention tools, such as developing a greatly, effective HIV vaccine, to better reduce HIV infections. An HIV vaccine is the best long-term hope for ending AIDS. We are looking for healthy, 18-60 year old and HIV-negative people to join studies we conduct. SCREENING AND EDUCATION: 1.
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    The HIV Vaccine Trials Network (HVTN) and Columbia University Irving Medical Center are doing a study to learn more about SARS-CoV-2 infection and the COVID-19 disease that it can cause. The purpose of this study is to learn more about infection with and recovery from the virus called SARS-CoV-2. Some people know this virus by the name coronavirus. It can cause the disease called COVID-19. You are being asked to take part in this study because you are age 18 or older and have recovered from COVID-19.
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    The purpose of the study is to create a prospective observational cohort of healthcare workers to follow and test for COVID-19 antibodies over time to understand how long antibodies last in the blood after infection, and if they correlate with immunity. The other purpose is to describe psychosocial well-being during COVID-19. We want to follow you for a year with testing and questionnaires to learn answers to these questions. Please contact us for more information and thank you for your patience.
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to complete a brief online questionnaire at your leisure to find out if you meet basic study criteria.
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to complete a brief online questionnaire at your leisure to find out if you meet basic study criteria.
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    We are looking for HIV-negative individuals 18 to 60 years old who are interested in learning more about HIV prevention research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1-hour education visit to learn about the research we do. The education visit will help you decide if you want to participate in one of our studies. You will be compensated for the visit. Your responses to this questionnaire will be kept strictly confidential. We are currently enrolling into this study.
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    Almost 40,000 people get HIV in the U.S. each year and almost all occur via sexual contact, especially male-to-male contact. The number of new infections has decreased slightly each year, however, we need other HIV prevention tools, such as developing a greatly, effective HIV vaccine, to better reduce HIV infections. SCREENING AND EDUCATION: 1. We will ask you to complete an electronic pre-screen questionnaire to help us determine your eligibility. 2. If eligible, we will ask you to attend a one-on-one educational visit (compensation: $20-25).
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    We are looking for individuals over 18 years old who are interested in learning more about COVID-19 vaccine and COVID-19 prevention research studies. We will ask you to complete a brief questionnaire to find out if you may be eligible for one of our studies. We can then schedule a phone call, teleconference, or in-person education visit so you can learn about the research we do and decide if you want to participate in one of our studies. Your responses to this questionnaire will be kept strictly confidential.